ArticleFoods (Basel, Switzerland)2025
Novel Anti-Inflammatory Bioactive Peptide Derived from Yak Bone Collagen Alleviates the Skin Inflammation of Mice by Inhibiting the NF-κB Signaling Pathway and Modulating Skin Microbiota.
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New Insights into the Anti-Aging Mechanism of Collagen Peptides-Emphasis on Lysosomes and Mitochondria Function.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Food-derived anti-inflammatory bioactive peptides have garnered significant attention due to their wide sources, easy absorption, and high biosafety. Our preliminary study identified a novel anti-inflammatory peptide GPAGPSGPAGKDGR (GR14) from yak bone collagen, which significantly alleviates lipopolysaccharide-induced inflammatory responses in HaCaT cells, demonstrating potential applications in improving skin inflammation. The objective of this study is to validate the anti-inflammatory effects of GR14 at the skin level in living animals and elucidate its mechanism of action. In this study, a 1-chloro-2,4-dinitrobenzene (DNCB)-induced skin inflammation mouse model was established. Results indicated that the GR14 intervention significantly improved skin manifestations and serum inflammatory cytokine levels in model mice. Compared to the model group, the high-dose treatment group demonstrated 33.61%, 40.55%, 22.18%, and 31.25% reductions in interleukin-6, interleukin-1β, tumor necrosis factor-α, and nitric oxide levels, respectively. Western blotting confirmed that GR14 intervention significantly inhibited the phosphorylation levels of P65 and IκB in the NF-κB signaling pathway. Microbiota analysis revealed that GR14 intervention effectively restored the significant decreases in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.